Bratland, Åse
Munoz-Couselo, Eva http://orcid.org/0000-0001-7556-7608
Mortier, Laurent
Roshdy, Osama
González, Rene
Schachter, Jacob
Arance, Ana M.
Grange, Florent
Meyer, Nicolas
Joshi, Abhishek Jagdish http://orcid.org/0000-0002-7786-0039
Billan, Salem
Hughes, Brett G. M. http://orcid.org/0000-0002-1811-0537
Grob, Jean-Jacques
Ramakrishnan, Karthik
Ge, Joy
Gumuscu, Burak
Swaby, Ramona F.
Gutzmer, Ralf http://orcid.org/0000-0001-7921-2820
Funding for this research was provided by:
Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Article History
Received: 9 August 2023
Accepted: 12 October 2023
First Online: 9 November 2023
Declarations
:
: Åse Bratland received all support for the present manuscript from Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, personal and institutional payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Merck Sharp & Dohme and BMS and personal payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Sanofi, and is president of the Scandinavian Society of Clinical Oncology. Eva Munoz-Couselo received consulting fees from BMS, Merck Serono, Amgen, Pierre Fabre, Sanofi, and Roche, payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from BMS, Novartis, Sanofi, Merck Serono, and Pierre Fabre, support for attending meetings and/or travel from BMS, Novartis, Merck Serono, and Sun Pharma, and participates on a data safety monitoring board or advisory board for BMS. Laurent Mortier received support for attending meetings and/or travel from MSD, Merck, Novartis, BMS, and Pierre Fabre. Ana M. Arance received personal consulting fees from Pierre Fabre, Novartis, Roche, BMS, MSD, Sanofi, and Merck and personal payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Pierre Fabre, Novartis, Roche, BMS, MSD, Sanofi, and Merck. Florent Grange received consulting fees from Sanofi-Adventis, payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events and support for attending meetings and/or travel from BMS. Nicolas Meyer received institutional grants or contracts from BMS and MSD, personal consulting fees from BMS, MSD, Pierre Fabre, Merck, Sanofi, Sun Pharma, and Novartis, and support for attending meetings and/or travel from Pierre Fabre, MSD, and Novartis. Abhishek Jagdish Joshi received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Ipsen, Janssen, and BMS, and support for attending meetings and/or travel from Ipsen, Roche, AstraZeneca, and Janssen. Brett G. M. Hughes received all support for the present manuscript from Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, institutional grants from Amgen, and payment or honoraria for speaker’s bureau from Eisai. Jean-Jacques Grob received personal consulting fees from BMS, Novartis, Amgen, Philogen, MSD, Pierre Fabre, Roche, and Sun Pharma, payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from BMA and Novartis, support for attending meetings and/or travel from Pierre Fabre, MSD, and BMS, participates on a data safety monitoring board or advisory board for BMS, MSD, Pierre Fabre, Novartis, and Philogen, and is in receipt of equipment, materials, drugs, medical writing, gifts, or other services from Pierre Fabre. Karthik Ramakrishnan is an employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Joy Ge has stock or stock options in Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Burak Gumuscu has stock in Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and is an employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Ramona F. Swaby is a former employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time of the conduct of the study; she reports current employment at Genmab US, 777 Scudders Mill Road, Bldg 2, Plainsboro, NJ 08536. Ralf Gutzmer received all support for the present manuscript from Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, consulting fees for participation on an advisory board from Roche, BMS, MSD, Novartis, Amgen, Merck Serono, Almirall Hermal, Sun Pharma, Sanofi, Pierre Fabre, Bayer, Pfizer, and Immunocore, consulting fees for participation on a data safety monitoring board from 4SC, honoraria for lectures from Roche, BMS, MSD, Novartis, Amgen, Merck Serono, Almirall Hermal, Sun Pharma, Sanofi, and Pierre Fabre, payment or honoraria for medical writing from BMS, Pfizer, Merck/MSD, Roche, Sun Pharma, Sanofi/Regeneron, Amgen, and Pierre Fabre, support for attending meetings and/or travel from Roche, BMS, Sun Pharma, Merck-Serono, and Pierre Fabre, and institutional support for investigator-initiated trials/projects from Novartis, Pfizer, Johnson & Johnson, Amgen, Merck-Serono, Sun Pharma, Sanofi, Kyowa Kirin, Almirall. Osama Roshdy, Rene González, Jacob Schachter, and Salem Billan have no conflicts of interest to disclose.
: The study protocol and amendments were approved by the appropriate institutional review boards and ethics review committees at each institution (Supplementary Material Table 1). The study was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the Declaration of Helsinki. All participants provided written informed consent.